Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Although infection prevention is an essential part of every rheumatologist’s routine, balancing efficacy, risk and individual patient choices — all while contending with a seemingly constant flow of ...